Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Interest Expense : $-13.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lexicon Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -5.42 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lexicon Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -46.74 Mil. Lexicon Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -5.42 Mil. Lexicon Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexicon Pharmaceuticals Interest Expense Historical Data

The historical data trend for Lexicon Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Interest Expense Chart

Lexicon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-20.68

-14.54

-0.80

-2.78

-13.10

Lexicon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.10	-1.82	-1.96	-3.90	-5.42

Lexicon Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.10 Mil.

Lexicon Pharmaceuticals (NAS:LXRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexicon Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-5.42 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-46.74 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $104.77 Mil.

Lexicon Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Lexicon Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381

Website

https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Executives

Philippe Amouyal	director	C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats	director, officer: President and CEO	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner	officer: SVP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade	officer: EVP, Gen. Counsel	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott	officer: VP, Human Resources	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a.	director, 10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc	director, 10 percent owner	750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth	officer: VP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub	officer: SVP, Regulatory & QA	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander	officer: VP, Finance and Accounting	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz	officer: SVP, Chief Medical Officer	58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer	officer: VP, Finance & Acctg	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381